vendredi 3 mars 2017

Onco Actu du 3 mars 2017

1. Biologie

Understanding the DNA-Damage “First Responders”: John Petrini at Work [memorial Sloan Kettering Cancer Center]

Science Snaps: fixing a cellular ‘antenna’ [Cancer Research UK]

3. Prévention

March is Colorectal Cancer Awareness Month: Here are 6 prevention recommendations that confuse association with causation [HealthNewsReview]

3.5 Prévention - UV

Some Melanoma Survivors Are Still Getting Too Much Sun Exposure [NPR]

While Most Melanoma Survivors Limit Sun Exposure, Some Report Getting Suntans and Sunburns [AACR]

4. Dépistage, diagnostic et pronostic

Cancer Screening Test Use — United States, 2015 [MMWR]

4.13 Dép., diag. & prono. - Peau

Absent tumor-suppressors allow melanoma to thwart immunotherapy [MD Anderson Cancer Center]

5. Traitements

Experimental drug could prevent cancer DNA repair to boost radiotherapy effects [The Institute of Cancer Research]

Leukemia drug works so well that some patients are now quitting it [STAT]

5.10 Traitements - Essais

Sanofi launches new virtual trials offering with Science 37 [FierceBiotech]

5.12.2 Immunothérapies - CAR-T

Juno ditches lead CAR-T program following patient deaths [FierceBiotech]

5.2 Pharma

Karyopharm flags a PhII overall survival failure for lead drug selinexor in acute myeloid leukemia [EndPoints]

Chi-Med declares PhIII success for pioneering cancer drug in China, seeking quick OK [EndPoints]

5.2.1 Pharma - Partenariats

Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers [Boehringer Ingelheim]

5.2.3 Pharma - économie

Roche's Perjeta chalks up needed win in Herceptin combo trial, but questions remain [FiercePharma]

No Details Yet, But Genentech Drug Combo Wins in Big Breast Cancer Study [Xconomy]

Roche's New Drugs May Protect its Old Ones [Bloomberg]

Roche shares spike as PhIII breast cancer combo with Perjeta scores a success, Puma takes a beating [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

Buoyed by Dana-Farber-led research, FDA approves first oral drug for cancer-related diarrhea syndrome [Dana-Farber Cancer Institute]

5.4 Traitements - Economie

NICE expands reach of Erbitux in colorectal cancer [PharmaTimes]

5.9 AACR

Leaders Preview the AACR Annual Meeting 2017 [Cancer Research Catalyst]

6. Lutte contre les cancers

How employers can greatly transform cancer care [STAT]

6.1 Observation

Malignant Mesothelioma Mortality — United States, 1999–2015 [MMWR]

6.11 Patients

Living With Cancer: Who Needs Another Cancer? [NY Times]